CGAP
Case Studies
CGAP is Empowering Innovative Research & Clinical Care Collaborations
Case Studies
CGAP is Empowering Innovative Research & Clinical Care Collaborations
Undiagnosed Disease Network (UDN)
The UDN utilized CGAP’s customized rare disease variant callers to analyze thousands of whole genome samples and facilitate discovery across the UDN Cohort.
Undiagnosed Disease Network (UDN)
The UDN utilized CGAP’s customized rare disease variant callers to analyze thousands of whole genome samples and facilitate discovery across
the UDN Cohort.
Undiagnosed Disease Network (UDN)
The UDN utilized CGAP’s customized rare disease variant callers to analyze thousands of whole genome samples and facilitate discovery across
the UDN Cohort.
Multiple System Atrophy (MSA) Coalition
The MSA Coalition leverages CGAP’s case and cohort analysis workflows to uncover the genetic causes of MSA, a rare neurodegenerative disorder.
Multiple System Atrophy
(MSA) Coalition
The MSA Coalition leverages CGAP’s case and cohort analysis workflows to uncover the genetic causes of MSA, a rare neurodegenerative disorder.
Multiple System Atrophy
(MSA) Coalition
The MSA Coalition leverages CGAP’s case and cohort analysis workflows to uncover the genetic causes of MSA, a rare neurodegenerative disorder.
Brigham Genomic Medicine (BGM)
As a co-developer of CGAP, BGM is using CGAP to identify novel gene-disease associations in patients and families with unsolved rare genetic diseases.
Brigham Genomic Medicine (BGM)
As a co-developer of CGAP, BGM is using CGAP to identify novel gene-disease associations in patients and families with unsolved rare genetic diseases.
Brigham Genomic Medicine (BGM)
As a co-developer of CGAP, BGM is using CGAP to identify novel gene-disease associations in patients and families with unsolved rare genetic diseases.
People Powered Medicine (PPM)
PPM used CGAP to identify the genetic variants associated with exceptional response to cancer treatments.
People Powered Medicine (PPM)
PPM used CGAP to identify the genetic variants associated with exceptional response to cancer treatments.
People Powered Medicine (PPM)
PPM used CGAP to identify the genetic variants associated with exceptional response to cancer treatments.
PROACTIVE Research Clinical Study
The PROACTIVE pilot project assessed CGAP’s performance and found that CGAP was able to successfully identify all actionable germ-line variants across all examined clinical cancer cases.
PROACTIVE Research
Clinical Study
The PROACTIVE pilot project assessed CGAP’s performance and found that CGAP was able to successfully identify all actionable germ-line variants across all examined clinical cancer cases.
PROACTIVE Research Clinical Study
The PROACTIVE pilot project assessed CGAP’s performance and found that CGAP was able to successfully identify all actionable germ-line variants across all examined clinical cancer cases.